Expanding its haematology portfolio, Swedish Orphan Biovitrum (Sobi) has agreed to acquire Dova Pharmaceuticals for up to US$915 M. The deal gives Sobi access to Doptelet, a second generation small-molecule agonist used in the treatment of thrombocytopenia by increasing platelet count. Doptelet is also being investigated in a Phase III trial for the treatment of chemotherapy-induced thrombocytopenia which currently has no approved treatments.